|
Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04) |
|
| Monoclonal antibodies |
TNF inhibitors ( Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
|
|
| -imus |
|
|
| -cept (Fusion protein) |
|
|
| Other |
|
|
